CRISPR Therapeutics
CRSP
448 hedge funds and large institutions have $3.22B invested in CRISPR Therapeutics in 2024 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 157 increasing their positions, 126 reducing their positions, and 74 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 157 | Existing positions reduced: 126
9% more capital inflows, than outflows
Capital inflows: $273M | Capital outflows: $250M
7% more call options, than puts
Call options by funds: $127M | Put options by funds: $119M
0.13% more ownership
Funds ownership: 70.01% → 70.14% (+0.13%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
6% less funds holding
Funds holding: 479 → 448 (-31)
43% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 74
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$52M |
| 2 |
Farallon Capital Management
San Francisco,
California
|
+$30.7M |
| 3 |
BlackRock
New York
|
+$13.4M |
| 4 |
Tang Capital Management
San Diego,
California
|
+$11.6M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avoro Capital Advisors
New York
|
-$28.6M |
| 2 |
Morgan Stanley
New York
|
-$28.2M |
| 3 |
ARK Investment Management
St. Petersburg,
Florida
|
-$21.9M |
| 4 |
Barclays
London,
United Kingdom
|
-$11M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.4M |
CRSP Hedge Fund Activity: Q2 2024 in Review
448 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2024, worth a combined $3.22B — down 21% from $4.09B a quarter earlier.
Sellers outnumbered buyers: 74 funds closed out of CRSP and 42 opened new positions — a net loss of 32 holders — while 126 trimmed existing stakes and 157 added.
The largest buyer was State Street, adding an estimated $52M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $28.6M sold.
- 448 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2024, down from 479 in Q1 2024.
- Funds reported $3.22B of CRISPR Therapeutics stock for Q2 2024, down 21% quarter-over-quarter.
- 42 funds opened new CRISPR Therapeutics positions in Q2 2024 and 74 closed out, a net change of -32 holders.
- The largest CRISPR Therapeutics buyer in Q2 2024 was State Street, an estimated $52M added.
- The largest CRISPR Therapeutics seller in Q2 2024 was Avoro Capital Advisors, an estimated $28.6M sold.
Based on aggregated 13F filings for Q2 2024.